Qube Research & Technologies (QRT)
RPRX icon

Qube Research & Technologies (QRT)’s Royalty Pharma RPRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2M Sell
1,412,112
-112,399
-7% -$5.85M 0.07% 351
2026
Q1 		$73.1M Sell
1,524,511
-944,670
-38% -$41.4M 0.08% 308
2025
Q4 		$95.4M Sell
2,469,181
-12,590
-0.5% -$480K 0.1% 260
2025
Q3 		$87.6M Buy
2,481,771
+2,185,366
+737% +$79.1M 0.09% 274
2025
Q2 		$10.7M Sell
296,405
-1,664,313
-85% -$55.1M 0.01% 1249
2025
Q1 		$61M Buy
1,960,718
+371,221
+23% +$11.8M 0.07% 342
2024
Q4 		$40.5M Sell
1,589,497
-345,476
-18% -$9.16M 0.05% 450
2024
Q3 		$54.7M Buy
1,934,973
+255,838
+15% +$7.09M 0.08% 325
2024
Q2 		$44.3M Buy
1,679,135
+908,455
+118% +$25.2M 0.07% 326
2024
Q1 		$23.4M Sell
770,680
-1,294,847
-63% -$38.2M 0.04% 517
2023
Q4 		$58M Buy
2,065,527
+354,655
+21% +$9.75M 0.11% 227
2023
Q3 		$46.4M Buy
1,710,872
+531,529
+45% +$15.8M 0.12% 211
2023
Q2 		$36.3M Buy
1,179,343
+750,586
+175% +$25.4M 0.13% 213
2023
Q1 		$15.4M Sell
428,757
-363,288
-46% -$13.5M 0.07% 319
2022
Q4 		$31.3M Buy
792,045
+468,762
+145% +$19.6M 0.17% 156
2022
Q3 		$13M Buy
323,283
+266,953
+474% +$11.4M 0.08% 347
2022
Q2 		$2.37M Sell
56,330
-213,523
-79% -$8.75M 0.02% 746
2022
Q1 		$10.5M Buy
269,853
+211,285
+361% +$8.3M 0.09% 290
2021
Q4 		$2.33M Sell
58,568
-24,636
-30% -$957K 0.02% 790
2021
Q3 		$3.01M Sell
83,204
-3,742
-4% -$145K 0.04% 557
2021
Q2 		$3.56M Buy
+86,946
New +$3.7M 0.04% 514
2020
Q4 		– Sell
-71,728
Closed -$3.02M – 2143
2020
Q3 		$3.02M Buy
+71,728
New +$3.08M 0.04% 510

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RPRX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Royalty Pharma (RPRX) stake by 7.4% in Q2 2026, selling an estimated $5.85M and leaving 1,412,112 shares worth $79.2M. The position accounts for 0.07% of the portfolio, ranked #351.

Qube Research & Technologies (QRT) first reported a position in RPRX in Q3 2020 and has held it in 22 quarters since. The position peaked at $95.4M in Q4 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 1,412,112 shares of Royalty Pharma worth $79.2M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 112,399 Royalty Pharma shares in Q2 2026, an estimated $5.85M.
  • Royalty Pharma made up 0.07% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #351 holding.
  • Qube Research & Technologies (QRT) first reported a position in Royalty Pharma in Q3 2020 and has held it in 22 quarters since.
  • Qube Research & Technologies (QRT)'s Royalty Pharma position peaked at $95.4M in Q4 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.